Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.65 - $11.00
Previous CloseN/A
Volume16.79K
Average Volume (3M)180.47K
Market Cap
$333.77M
Enterprise Value$23.05M
Total Cash (Recent Filing)$201.91M
Total Debt (Recent Filing)$8.26M
Price to Earnings (P/E)―
Beta-1.68
Next Earnings
Mar 16, 2026EPS EstimateN/A
Last Dividend Ex-Date
Feb 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding51,191,772
10 Day Avg. Volume413,215
30 Day Avg. Volume180,465
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.45
Price to Sales (P/S)0.00
P/FCF Ratio-8.03
Enterprise Value/Market Cap0.07
Enterprise Value/Revenue48.03
Enterprise Value/Gross Profit-235.23
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$22.50Price Target Upside223.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market AdoptionDetalimogene is positioned to capture sizable market share, particularly within the community practice setting.
Regulatory AdvantagesThe FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation allows heightened regulatory interaction and has historically compressed timelines, increasing detalimogene’s chances of capturing share.
Bears Say
Competitive BenchmarkingThe bar for CR durability is high, with cretostimogene showing superior remission rates and a clean safety profile.
Price Target AdjustmentThe price target was reduced from $16 to $14.
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $2.65 and its highest was $11.00 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $333.77M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Mar 16, 2026 which is in 177 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Sep 11, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.498 by -$0.072.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 51,191,772 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.498. Following the earnings report the stock price went down -5.776%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
enGene Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (223.28% Upside)
$22.50 (223.28% Upside)
Blogger Sentiment
Bearish
ENGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.26%
12-Months-Change
Fundamentals
Return on Equity
-43.95%
Trailing 12-Months
Asset Growth
-7.99%
Trailing 12-Months
Company Description
enGene Holdings
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$22.50
▲(223.28% Upside)
Technical Analysis
Ocugen
―
Cidara Therapeutics
―
Corvus Pharmaceuticals
―
Tevogen Bio Holdings
―
CARGO Therapeutics, Inc.
―
Ownership Overview
19.13% Insiders
0.27% Mutual Funds
66.89% Other Institutional Investors
13.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---